Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Although it surprised many in India to have Fujifilm's name associated with generic drugs, its penchant to explore the Japanese market coincides with the Japanese government's mission to encourage use of generic substitutes in Japan to drive costs down.

You may also be interested in...

Dr. Reddy's Labs Saved From Poor India Showing By North America Market Growth, Biosimilars

MUMBAI - Dr. Reddy's Laboratories Ltd. faced an unexpected slowdown in its home market as sales growth in India slipped to just 6% during the first quarter - remarkably lower than the industry average of 14% to 15% - but a 69% rise in sales of its biosimilars products like monoclonal antibody Reditux (rituximab) powered revenues to a respectable $66 million, against $62 million achieved during the same period last year

Teva Buys Japanese Generics Company For $460 Mil.

Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company

Fujifilm Acquires Two Merck Bio Units Looking To Ramp Up Pharma Business

TOKYO - Fujifilm Corp. plans to acquire two Merck & Co. Inc. biopharma units to make a long-term push into biopharmaceutical manufacturing and distribution, possibly leveraging its pharmaceutical subsidiary, Toyama Chemical, Fuijifilm said

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts